The IPO, which opened for subscription on July 14 in the primary market, got fully subscribed on the second day of the bidding process.
The category for qualified institutional buyers fetched 182.65 times subscription, while the non-institutional investors quota got subscribed 44.36 times. Meanwhile, the retail investors had subscribed by 5.64 times and the employees quota witnessed 6.60 times subscriptions.Earlier, the company had raised ₹1,016 crore from anchor investors.
In the unofficial market, shares of Anthem Biosciences are trading at a grey market premium (GMP) of ₹144, indicating a listing gain of 25% over the issue price.
However, it is important to note that grey market premiums are just an indicator of how the company’s shares are stacked up in the unlisted market and are subject to change rapidly.Anthem Biosciences sold its shares in a fixed price band of ₹540 to ₹570. At the upper price band, the company’s valuation stands at over ₹31,800 crore.
Anthem Biosciences raised ₹3,395 crore through an initial share sale, which comprises of entirely an offer-for-sale by existing shareholders including investors Viridity Tone, and Portsmouth Technologies.
The company will not receive any from the public issue. All the funds, excluding offer expenses, will go to selling shareholders.
Incorporated in 2006, Anthem Biosciences is a full-service CRDMO offering end-to-end solutions to pharma and biotech firms, covering drug development from early research to commercial manufacturing through an integrated model that simplifies processes and reduces compliance hassles.
JM Financial is the book-running lead manager of the Anthem Biosciences IPO, while Kfin Technologies is the registrar.
The allotment for the Anthem Biosciences IPO is expected to be finalised on July 17, while the shares will be listing on BSE, NSE with a tentative listing date fixed as July 21, 2025.
